Evaluating vibegron for the treatment of overactive bladder.

Article Details

Citation

Rechberger T, Wrobel A

Evaluating vibegron for the treatment of overactive bladder.

Expert Opin Pharmacother. 2020 Sep 29:1-9. doi: 10.1080/14656566.2020.1809652.

PubMed ID
32993398 [ View in PubMed
]
Abstract

INTRODUCTION: Vibegron is a very selective new beta3-adrenergic receptor agonist introduced recently to clinical practice for OAB patients, which offers an alternative option for to antimuscarinic drugs. AREAS COVERED: This review presents the current knowledge concerning the mechanism of action, pharmacokinetics, and pharmacodynamics of vibegron. Moreover, it presents an overview of preclinical and phase II and phase III clinical studies on the efficacy, tolerability, and safety of this agent in patients suffering from OAB. EXPERT OPINION: Clinical studies confirmed efficacy and safety of vibegron in OAB patients. Vibegron differ from well-known mirabegron with regards to its pharmacological pro fi le because it is metabolized independently from CYP3A4, 2D6, or 2C9 and therefore is less likely to cause a drug-drug interaction. Moreover, since this drug does not penetrate the blood-brain barrier, it could become the drug of choice in OAB patients with cognitive impairment. These properties have paved the way in near future for better-tailored treatments for OAB patients.

DrugBank Data that Cites this Article

Drugs
Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
VibegronBeta-3 adrenergic receptorProteinHumans
Yes
Agonist
Details
Drug Interactions
DrugsInteraction
Vibegron
Trospium
Trospium may increase the smooth muscle relaxing activities of Vibegron.
Vibegron
Darifenacin
Darifenacin may increase the smooth muscle relaxing activities of Vibegron.
Vibegron
Tolterodine
Tolterodine may increase the smooth muscle relaxing activities of Vibegron.
Vibegron
Oxybutynin
Oxybutynin may increase the smooth muscle relaxing activities of Vibegron.
Vibegron
Flavoxate
Flavoxate may increase the smooth muscle relaxing activities of Vibegron.